Application of il-28 and il-29 for treatment carcinoma and autoimmune disorders

FIELD: medicine.

SUBSTANCE: group of the inventions refers to medicine, namely to oncology and immunology and can be used for treating renal cell carcinoma or thymoma. The method is implemented as follows: Polypeptide containing amino acid precipitations 1-182 of a sequence SEQ ID NO:29 or precipitations 1-176 of a sequence SEQ ID NO: 159, is used for preparing a drug for treating renal cell carcinoma. Another aspect of the invention concerns application of polypeptide containing amino acid precipitations 1-176 of the sequence SEQ ID NO: 159 for preparing a drug for treating thymoma.

EFFECT: application of the inventions allows improving clinical effectiveness in said diseases due to tumour induction polypeptide reaction with reducing cytotoxic by-effects.

5 cl, 35 tbl, 6 dwg, 46 ex

 

The text descriptions are given in facsimile form.

1. The use of a polypeptide containing amino acid residues 1-182 of the sequence SEQ ID NO:29 or amino acid residues 1-176 of the sequence SEQ ID NO:159, to obtain drugs for the treatment of kidney cancer.

2. The use of a polypeptide containing amino acid residues 1-176 of the sequence SEQ ID NO:159, to obtain drugs for the treatment of thymoma.

3. The use according to claim 1 or 2, where the additional polypeptide is a recreational contains polyethylene glycol.

4. The use according to claim 3, where the glycol is monomethoxy-PEG-Pro spinaldesign.

5. The use according to claim 3 or 4, wherein the polyethylene glycol has a molecular mass of approximately 20 kDa.



 

Same patents:

FIELD: medicine.

SUBSTANCE: invention concerns biochemistry and medicine. There is offered therapeutic application of yessotoxins as inhibitors of human tumour cell growth. The mechanism of action of yessotoxin (YTX) is associated with activation of cell phosphodiesterases and respectively with decreasing the content of cyclic adenosine monophosphate in cytosol. This cytotoxic effect of YTX with respect to tumour cells can be applied as a strategy to develop preparation effective in treating tumour processes.

EFFECT: inhibition of human hepatocellular carcinoma cell growth following introduction of YTX.

3 cl, 1 dwg, 1 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to application of transcript modifying agents to prevent the genetic grading of malignant cells required to resist cell damage and their survival in chemotherapy or radiotherapy. There is applied a pharmaceutical composition containing hydralazine and valproic acid or its salt, e.g. magnesium valproate, in a pharmaceutically acceptable carrier to assist in cancer treatment along with chemotherapy or radiotherapy.

EFFECT: invention provides synergetic effect in cancer treatment by conventional therapeutic agents.

5 cl, 5 ex, 9 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to drugs and concerns a pharmaceutical composition for percutaneous delivery of 4-hydroxy-tamoxsifen which contains 4-hydroxy-tamoxifen in an alcohol water solution where amount of spirit is 35-99.9 wt % of the composition weight, and about 45%-55%, about 46%-54%, about 47%-53%, about 48%-52%, about 49%-51% or about 50% of said 4-hydroxy-tamoxifen is found as an isomer Z and remained amount of said 4-hydroxy-tamoxifen is in the form of isomer E. There is also disclosed method for preparing a pharmaceutical composition for percutaneous delivery of 4-hydroxy-tamoxifen.

EFFECT: preparation of the pharmaceutical composition which contains an equilibrium ratio of isomers E and Z of 4-hydroxy-tamoxifen.

13 cl, 9 dwg, 4 tbl, 6 ex

FIELD: chemistry.

SUBSTANCE: present invention relates to four defined crystalline polymorphous forms of the monohydrate of a compound A having the following chemical composition:

.

Compound A. These four polymorphous forms, denoted here as forms I, II, III and IV, exhibit CXC chemokine receptor ligand activity.

EFFECT: invention relates to a pharmaceutical composition based on said compounds, to use thereof for treating different diseases and to methods for synthesising the said polymorphous forms.

58 cl, 2 tbl, 4 dwg

FIELD: chemistry.

SUBSTANCE: invention relates to new crystalline modifications of N-α-(2,4,6-triisopropylphenylsulphonyl)-3-hydroxyamidino-(L)-phenylalanine-4-ethoxycarbonyl piperazide and/or its salts. Such crystalline modifications have high stability particularly at low hygroscopicity compared to known amorphous forms of the compound.

EFFECT: invention relates to a method of obtaining such new crystalline modifications, to pharmaceutical compositions containing these new crystalline modifications and their use as an anti-tumour agent.

26 cl, 7 tbl, 13 ex, 20 dwg

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to oncology and can be used for treatment of pulmonary cancer. Essence of invention lies in the fact that before initiation of treatment an extracorporeal ray treatment of 300 ml of patient's blood in red diapason range with λ=0.67 mcm in continuous-wave mode during 3 minutes at maximum radiant power 17 mlW, radiation level w=3.06 J/cm2 is conducted. Then irradiated blood is incubated with cytostatic in therapeutic dose during 40 minutes at T=37°C, whereafter the irradiated blood with cytostatic is inserted to patient intravenously by drop infusion. During course of treatment three or four such procedures are conducted at three days interval, in total one or two courses of treatment at three weeks interval are conducted.

EFFECT: use of this invention enables to transfer patients with tumors of stage three or four into resectable condition by means of stimulating involution and regress of neoplastic deposits from lymphonodus at neoadjuvant therapy delivery of photo- modified autoblood.

2 ex

FIELD: medicine.

SUBSTANCE: group of invention concerns medicine, namely to oncology and can be used in prostate cancer treatment. The methods of the invention imply administration of a composition containing therapeutically effective quantities of supercritical extracts of rosemary, curcuma, marjoram and ginger, as well as therapeutically effective quantities of water-alcoholic extracts of holy basil, ginger, curcuma, Scutellaria baicalensis, rosemary, green tea, Polygonum cuspidatum, Coptis chinensis Franchet and barberries.

EFFECT: inhibition of prostate cancer cell growth due to the effect of COX-2 composition without any significant side-effects.

36 cl, 1 tbl, 5 dwg, 4 ex

FIELD: chemistry.

SUBSTANCE: invention relates to a method for regiospecific synthesis of rapamycin 42-ester derivatives of formula , where R is ketal isopropylidene substituted with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid, linear or branched C1-C10 alkyl, which possibly contains a halogen, C2-C8 alkenyl, or phenyl, where the said method involves acylation of 42-hydroxyrapamycin with an acyl donor in the presence of lipase. The invention also relates to regiospecific preparation of rapamycin 42-ester from ketal isopropylidene substituted with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid in the presence of lipase.

EFFECT: increased output of the product under mild conditions.

13 cl, 12 ex

FIELD: chemistry.

SUBSTANCE: invention relates to novel condensed heterocylic protein kinase modulators of formula I where L1 and L2 independently denote a bond, and R1 and R2 denote a substituted or unsubstituted heteroaryl or a substituted or unsubstituted aryl, as well as to pharmaceutical compositions containing such compounds, and methods of using the compounds to prepare medicine for diseases mediated by protein kinase activity.

EFFECT: increased effectiveness of using the compounds.

24 cl, 20 tbl, 24 ex

FIELD: chemistry.

SUBSTANCE: invention relates to novel compounds selected from compounds of formulae Ia, lb and Ic, which have protein kinase activity on kinase selected from CDKs, Aurora, Jak2. Rock, CAMKI, FLT3, Tie2, TrkB, FGFR3 and KDR, abnormal activity of which is observed in pathological conditions such as nonmalignant and malignant proliferative diseases. In compounds of formulae , and : n equals 0 or 1, R1 is selected from a group comprising halogen, C1-C6alkyl, C1-C6alkoxy, halogen-substituted CpC6alkyl and halogen-substituted C1-C6alkoxy, R2 is selected from a group comprising phenyl, 6-member heteroaryl containing 1-2 nitrogen atoms in the heteroaryl ring as heteroatoms, and phenyl(C0-C4)alkyl, where the said phenyl and heteroaryl in R2 are optionally substituted with 1-3 radicals independently selected from a group comprising halogen, C1-C6alkyl, C1-C6alkoxy, halogen-substituted C1-C6alkyl, halogen-substituted C1-C6alkoxy, -S(O)0-2R5, -COOR5 and -NR5C(O)R6, where R5 is selected from C1-C6alkyl, and R6 is selected from phenyl, where the said phenyl in R6 is optionally substituted with 1-3 radicals independently selected from a group comprising C1-C6alkyl, C1-C6alkoxy, halogen-substituted C1-C6alkyl and halogen-substituted C1-C6alkoxy, X is selected from CR7 and N, where R7 is selected from hydrogen or C1-C6alkyl.

EFFECT: increased effectiveness of using the compounds.

7 cl, 3 dwg, 1 tbl, 3 ex

FIELD: medicine.

SUBSTANCE: human IL-18 polypeptide is introduced to the patient in the therapeutically effective amount.

EFFECT: technique allows for faster wound healing with the developed effective doses of human IL-18 polypeptide.

13 cl, 2 tbl, 3 ex, 7 dwg

FIELD: medicine, veterinary science.

SUBSTANCE: method involves oral application of preparation fascocide in a single dosage 1 g per 10 kg of body weight with the concentrated forage and subcutaneous introduction of preparation ronkoleukine in a dosage 5000 ME per one kg of body weight within middle third of neck, twice every 72 hours.

EFFECT: method improves therapeutic effectiveness of antiparasitic actions, stimulates nonspecific resistance factors, normalises protein metabolism and protein synthesising function of the liver.

4 tbl, 4 ex

FIELD: medicine.

SUBSTANCE: invention concerns medicine, namely otorhinolaryngology and can be used for prediction of clinical effectiveness in chronic purulent rhinosinusitis. The method involves prediction of clinical effectiveness in chronic purulent rhinosinusitis provided the recombinant cytokine immunotherapy based on genetic typing of polymorphism of cytokine gene. The therapy includes recombinant interleukine-1β, and the presence of low-producing allele cytokine gene IL-1β, increased phagocytic activity of neutrophils ensured by higher level IL-8 is predicted with high clinical effectiveness secured.

EFFECT: application of the invention allows predicting efficiency of the forthcoming therapy with recombinant interleukine-1β ensured by determination individual susceptibility of each patient considering genotype-based functional activity of cells.

2 cl, 4 dwg, 4 ex

FIELD: medicine.

SUBSTANCE: invention is related to the field of medicine, in particular to microbiology and immunology and may be used in development of vaccine against melioidosis. Substance of method consists in the fact that animals are immunised with surface melioidosis complex, which consists of antigen 6 (AG6) and antigen d, which is injected to animals subcutaneously, twice, with interval of 10 days, in doses of 30 mcg by protein for mice or 150 mcg for rats. Simultaneously with primary immunisation recombinant interferon-γ - ingaron is injected in doses 8 ME for mice or 120 ME for rats, and in case of secondary immunisation, recombinant interleukin-2 - roncoleukin in doses of 0.6 mcg for mice or 10 mcg for rats, besides cytokines are injected to animals subcutaneously, daily, simultaneously with immunisation and in the next 2 days. In 21 days after primary immunisation animals are infected with 4-32 LD50 of highly virulent strain 100 of melioidosis causative agent, in 30 days after infection parametres of animal lethality are identified.

EFFECT: application of invention makes it possible to increase protectivity of melioidosis antigens due to cytokine stimulation of primary and secondary immune response to these antigens.

5 tbl, 2 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to dermatology, and can be used for treatment or rejuvenation of human skin. It is ensured by introduction of autogenous fibroblasts suspended in physiologic saline and hyaluronic acid in treatment or rejuvenation region. The skin is prepared with growth fibroblast medium with biologically active substances (BAS) - growth medium factors including fibroblast growth in the form of gel.

EFFECT: invention provides smoothing of wrinkles, higher skin elasticity.

2 ex, 2 tbl, 52 cl

FIELD: biotechnology.

SUBSTANCE: invention relates to biotechnology, particularly to genetic engineering and it can be used in the biomedical industry to produce active medications of interleukin-29 (IL-29). Mutant forms of IL-29 (SEQ ID NO: 27, 29, 40, 41, 149 and 159) were offered with substitution of the cysteine residue in the position in accordance with position 171 of the aminoacid sequence of a mature protein of a wild type that are characterised by a correct formation of intramolecular disulfide bonds and accordingly they provide production of polypeptides with an antiviral activity as homogeneous medications at expression in the heterologous system.

EFFECT: vector structures and the host cells transformed by these structures for the expression of new versions of IL-29 are described.

15 cl, 37 tbl, 45 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine and namely gastroenterology and surgery and deals with preventive treatment and treatment of suppurative complications at acute destructive pancreatitis. For that purpose against complex conservative drug therapy there performed is sanation diagnostic abdominoscopy, and polyethylene cannula is installed in the round hepatic ligament. 70-80 ml of leukosuspension is obtained from the patient's blood on the 1st, 3rd, and 5th days of the post-operation period by means of plasmapheresis, which is then incubated with Ronkoleukin in quantity of 500000 units. Leukosuspension incubation lasts for 60 minutes at the temperature of 37°C. Then leukosuspension with Ronkoleukin is injected through the above cannula to the round hepatic ligament.

EFFECT: method provides effective treatment of acute destructive pancreatitis and namely owing to increase of local immunity, and as the result, quick normalisation of clinic laboratory values.

1 ex

FIELD: medicine.

SUBSTANCE: invention relates to field of medicine, namely to fields of surgery and resuscitation science and can be used in treatment of patients with acute destructive appendicitis, confirmed intra-operatively. Draining of right iliac fossa or tamponade and draining of right iliac fossa are performed and anti-bacterial therapy is carried out. In case of performing appendectomy by traditional or laparoscopic method, polyethylene catheter is installed in retroperitoneal space into right iliac fossa, through which additionally introduced is roncoleukin, incubated during 60 minutes at temperature 37°C with obtained by plasmapheresis patient's leukosuspension in amount 70-80 ml on 1,3,5 day of post-operation period.

EFFECT: method allows to increase local immunity, realise prophylaxis of suppurative complications in case of acute destructive appendicitis.

2 ex

FIELD: medicine.

SUBSTANCE: invention concerns medicine, in particular, to gastroenterology, and concerns treatment of chronic virus hepatitis B. For this purpose Roncoleukin is intravenously driply administered in a dose of 500 mg, with rate of 1-2 ml/min, during 4-6 h 2 times a week - 1 month. Then the specified preparation is administered subcutaneously, 1 ml 2 times a week within 2 months.

EFFECT: elimination of a cellular link of immunity imbalance, rapid normalisation of clinico-laboratory indicators without by-effects presentation.

2 ex

FIELD: medicine.

SUBSTANCE: invention concerns medicine, namely odontology and can be used for treatment of pyoinflammatory diseases of soft tissues of maxillofacial area. The way is carried out as follows. Roncoleukin is administered in the exudative-inflammatory phase of a purulent wound process in the form of a solution with 500000 ME dose of active substance, into a wound preliminary irrigated by means of 10.0 ml of sterile 0.9% sodium chloride, on the turundas, dilluted either with 0.9%, or 10% sodium chloride solution. Thus a bandage from 20% dimexid solution is imposed on periphery of a purulent wound, spending daily dressings. In a proliferative phase - an irrigation of a wound using the Roncoleukin solution is combined with 500000 ME dose of active substance, diluted with 0.9% solution of sodium chloride and salve dressings with preparations on a water-soluble basis; dressings are spent in a day. The way allows normalising indicators of local immunity of a purulent wound and an oral cavity, to strengthen functional activity of phagocytes of a wound, to accelerate purification of wounds from necrotic masses, to optimise terms of occurrence of granulations.

EFFECT: possibility to normalise indicators of local immunity of a purulent wound and an oral cavity, to strengthen functional activity of phagocytes of a wound, to accelerate purification of wounds from necrotic masses, to optimise terms of occurrence of granulations.

3 tbl, 3 ex

FIELD: medicine, phthisiology.

SUBSTANCE: method involves administration of roncoleukin by lymphotropic route: subcutaneously, in region of pretracheal cellular tissue in the equal dose 1/4-1/5 of the average daily therapeutic dose, once in one or two days, 3 injections for a course. Invention provides the local delivery of roncoleukin to the injure zone directly that promotes to making depot of the latter in the injure focus and to the rapid elimination of pathogen from body of patients. Invention can be used for correction of immune insufficiency in patients with pulmonary tuberculosis.

EFFECT: improved method for correction.

2 ex

Up!